Abstract:Focal adhesion kinase (FAK) is a 125 kDa nonreceptor tyrosine kinase that plays an important role in many carcinomas. Thus, the targeting of FAK by small molecules is considered to be promising for cancer therapy. Some FAK inhibitors have been reported as potential anticancer drugs and have entered into clinical development; for example, VS-4718 is currently undergoing clinical trials. However, the lack of crystal structural data for the binding of VS-4718 with FAK has hindered the optimization of this anticancer agent. In this work, the VS-4718/FAK interaction model was obtained by molecular docking and molecular dynamics simulations. The binding free energies of VS-4718/FAK were also calculated using the molecular mechanics generalized Born surface area method. It was found that the aminopyrimidine group formed hydrogen bonds with the C502 residue of the hinge loop, while the D564 residue of the T-loop interacted with the amide group. In addition, I428, A452, V484, M499, G505, and L553 residues formed hydrophobic interactions with VS-4718. The obtained results therefore provide an improved understanding of the interaction between human FAK and VS-4718. Based on the obtained binding mechanism, 47 novel compounds were designed to target the adenosine 5'-triphosphate-binding pocket of human FAK, and ensemble docking was performed to assess the effects of these modifications on the inhibitor binding affinity. This work is also expected to provide additional insights into potential future target design strategies based on VS-4718.

Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors.

Development of Novel Focal Adhesion Kinase (FAK) Inhibitors for Targeting Cancer: Structural Insights and Therapeutic Potential

Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics

Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy

Focal adhesion kinase: from biological functions to therapeutic strategies

Molecular description of pyrimidine-based inhibitors with activity against FAK combining 3D-QSAR analysis, molecular docking and molecular dynamics

Molecular Docking, Molecular Dynamics Simulations, and Free Energy Calculation Insights into the Binding Mechanism between VS-4718 and Focal Adhesion Kinase

Exploring the interaction between human focal adhesion kinase and inhibitors: a molecular dynamic simulation and free energy calculations

Research and Development of Focal-Adhesion Kinase(FAK) and the Inhibitors

Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders

Synthesis, Biological Evaluation and Molecular Docking Studies of Novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone Derivatives

FAK expression regulation and therapeutic potential

Discovery of novel pyrrolo [2,3-d] pyrimidine derivatives as potent FAK inhibitors based on cyclization strategy

Synthesis, Molecular Modeling, and Biological Evaluation of 1,2,4-Triazole Derivatives Containing Pyridine As Potential Anti-Tumor Agents

[The study of physicochemical parameters of the blood serum and renal function in children with some pathology of the internal organs].

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Sulfonamide Moiety As Novel FAK Inhibitors

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Dithiocarbamate Moiety As Novel FAK Inhibitors with Antitumor and Anti-Angiogenesis Activities.

Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction

Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment

Discovery of a series of 1,3,4-oxadiazole-2(3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors.

Design, synthesis and biological evaluation of novel FAK inhibitors with better selectivity over IR than TAE226